A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Modular CLDN18.2-targeting PG CAR-T Therapy (IBI345) in Patients with CLDN18.2+ Solid Tumors (FPN: 1054P)

S. Qin¹, W. Tian², M. Li³, H. Wei⁴, L. Sun³, Q. Xie⁵, E. Lin⁶, D. Xu⁷, J. Tian⁴, J. Chen⁸, W. Lu⁸, N. Gao⁹, L.Chen¹⁰, J. Duo¹¹, L. Ye¹², T. Cheng¹³, Y. Sui³, C. Klein¹⁴, W. Chen²

Background

- Chimeric antigen receptor (CAR) T-cell therapy holds great promise for the treatment of solid tumors. However, how to avoid or minimize the "on-target off-tumor" effect of CAR-T therapy remains a major issue.
- We developed a P329G (PG) modular and switchable CAR technology, and report the first-in-human clinical results of a CLDN18.2-targeting PG CAR-T product (IBI345) for the treatment of CLDN18.2+ solid tumors.




Figure 1. Design of PG CAR-T

Methods

- This phase 1a study (NCT05199519) enrolled CLDN18.2-positive (≥1+, ≥1%) patients (pts) with advanced gastric cancer or pancreatic cancer who failed or were intolerant to standard therapy.
- **Treatment:** Pts received an infusion of IBI345 consisting of one dose of PG CAR-T cells at escalating doses of 50, $250*10^{6}$ cells plus ≥ 1 dose of CLDN18.2-targeting PG antibody (Ab) at a fixed dose of 1mg/kg Q3W after lymphodepletion preconditioning.
- **Objectives:** Safety and tolerability, pharmacokinetics and preliminary efficacy (per RECIST 1.1) of IBI345.

¹Department of Radiation Oncology, The First Affiliated Hospital of Soochow University, Suzhou, China, ³Department of Clinical Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of New Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department of Rev Drug Development, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department, Suzhou, China, ⁴Department, Innovent Cells Pharmaceuticals, Suzhou, China, ⁴Department, Suzhou, China, ⁴ Innovent Cells Pharmaceuticals, Suzhou, China, ⁵Department of Biologics (Suzhou, China, ⁶Department of Biologics (Suzhou, China, ⁸Process) Co., Ltd., Suzhou, China, ⁶Department of Biologics (Suzhou) Co., Ltd., Suzhou, China, ⁸Process) Development, Innovent Cells Pharmaceuticals, Suzhou, China, ¹⁰Translational Medicine, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, China, ¹²Manufacture Department, Innovent Cells Pharmaceuticals, Suzhou, China, ¹⁴Chemical Manufacturing and Control, Innovent Cells Pharmaceuticals, Suzhou, China, ¹⁴Chemical Manufacturing and Control, Innovent Cells Pharmaceuticals, Suzhou, China, ¹⁴Chemical Manufacture Department, Innovent Cells Pharmaceuticals, Suzhou, ¹⁴Chemi Pharmaceuticals, Suzhou, China, ¹³Quality Control, Innovent Cells Pharmaceuticals, Suzhou, China, ¹⁴Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland.

Table 1. Overview of Clinical and Biomar

IBI345 dose

IBI345 PG IgG 1mg/kg + PG CAR-T cells 50*1

IBI345 PG IgG 1mg/kg + PG CAR-T cells 250*




Figure 2. Clinical response and pharmacokinetics profile. TL: target lesion

Results						
arker Results for Each Individual Patient						
	Patient	Age (years)	Gender	Tumor Type	CLDN 18.2 expression	Best overall response
10^6	PT01	69	Male	Esophagogastric junction cancer (EGJC)	1+, 12%; 2+,3%; 3+, 0% H score 18, Low	Partial response (PR)
*10^6	PT02	64	Male	Gastric cancer (GC)	1+, 1%; 2+,0%; 3+, 0% H score 1, Low	Stable disease (SD)
	PT03	60	Male	Pancreatic cancer (PC)	1+, 0%; 2+, 5%; 3+, 90% H score 280, High	Stable disease (SD)
	PT04	68	Female	Pancreatic cancer (PC)	1+, 0%; 2+, 0%; 3+, 100% H score 300, High	Progressive disease (PD)

▲ PT01 died on day 336 after CAR-T infusion

Treatment duration

Response

PD

iCPD
Death

Subject ID

► PT01

PT02 PT03

PT04

Safety: As of Apr 7, 2023, 5 pts were treated with IBI345. All pts experienced treatment related adverse events (TRAEs) while 3 pts (60%) had grade ≥3 TRAEs. Common TRAEs were decreased appetite (4/5, grade ≥ 3 in 1 pt), neutrophil count decreased (2/5, all grade ≥ 3), white blood cell count decreased (2/5), pyrexia (2/5), blood creatinine increased (2/5) and vomiting (2/5). No cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) or treatment-related death occurred. Efficacy: For 4 efficacy-evaluable pts, the objective response rate (ORR) was 25% and disease control rate (DCR) was 75%.

Pharmacokinetics: CAR-T expansion and persistence were detected in all pts, with a median peak of 1,840 copies/ μ g gDNA (range: 1,500-4,020), a median time to peak of 16 days (range: 9-20), and a median persistence of 45 days (range: 35-127).

IBI345 demonstrated a manageable safety profile and preliminary efficacy in patients with CLDN18.2+ advanced solid tumors. To realize the full potential of this modular CAR-T cell product, the dose and regimen of the P329G Ab and CAR-T cells requires further exploration.

Study sponsored by Innovent Cells Pharmaceuticals.

Presenting author: Dr. Songbing Qin, Email: <u>qin92244@163.com</u> Corresponding author: Dr. Weichang Chen, Email: weichangchen@126.com

Conclusions

Acknowledgement

Contact information